SWOG clinical trial number
CTSU/A021602

Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)

Closed
Phase
Abbreviated Title
Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)
Status Notes
SWOG Champion Raphael Jonathan Strosberg, MD. - Effective immediately, Monday, August 7, 2023, A021602 (CABINET) is temporarily suspended to new patient registration. The study will remain temporarily suspended until the interim analysis described in Section 13.5 of the protocol has been completed.
Activated
07/18/2018

Research committees

Gastrointestinal Cancer

Treatment

Cabozantinib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unity (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2025

Phase 3 Trial of Cabozantinib in Previously Treated Advanced Neuroendocrine Tumors

J Chan;S Geyer;T Zemla;M Knopp;S Behr;S Pulsipher;F Lou;j Acoba;A Shergill;E Wolin;T Halfdanarson;B Konda;N Trikalinos;S Shaheen;N Vijayvergia;A Dasari;J Strosberg;E Kohn;M Kulke;E O'Reilly;J Meyerhardt New England Journal of Medicine

PMid: PMID39282913 | PMC number: PMC11821447

Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)

J Strosberg;T Zemla;S Geyer;M Knopp;S Behr;S Pulsipher;J Acoba;A Shergill;E Wolin;T Halfdanarson;B Konda;N Trikalinos;B Tawfik;N Raj;S Shaheen;N Vijayvergia;A Dasari;E O'Reilly;J Meyerhardt;J Chan ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666

Efficacy and Safety of Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors After Progression on Prior Therapy: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)

J Strosberg;T Zemla;S Geyer;S Pulsipher;S Behr;N Raj;N Vijayvergia;NA Dasari;J Meyerhardt;E Wolin;T Halfdanarson;J Chan ENETS (European Neuroendocrine Tumor Society) meeting (Mar 5-7, 2025, Krakow, Poland)

2023

Alliance A021602: Phase III, Double Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)

J Chan;S Geyer;F Ou;M Knopp;S Behr;T Zemla;A Jacoba;A Shergill;E Wolin;T Halfdanarson;N Trikalinos;B Konda;N Vijayvergia;N Dasari;N Dasari;J Strosberg;E Kohn;M Kulke;E O'Reilly;J Meyerhardt Annals of Oncology VOLUME 34, SUPPLEMENT 2, S1292; ESMO (October 20-24, 2023, Madrid, Spain), proferred paper presentation

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase